Inflammatory and immune-mediated diseases
3 European H2020 organizations list this as part of their work — 1 as their primary capability.
Most active in this area
- SANOFI-AVENTIS DEUTSCHLAND GMBH
Global pharma company contributing clinical data, compound libraries, and translational toxicology expertise to European diabetes and immunology research consortia.
“Active in BIOMAP (atopic dermatitis/psoriasis), ImmUniverse (immune-mediated diseases), 3TR (treatment non-response in autoimmunity), and RTCure (rheumatoid arthritis tolerance).”
DE18 projects - CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE
Belgian university hospital contributing clinical expertise in neuroscience, inflammatory disease, and AI-powered diagnostics to European research consortia.
“Coordinated BIOCYCLE on Crohn's disease treatment optimization and contributed to ImmunAID on autoinflammatory disorders.”
BE13 projects - GREATER GLASGOW HEALTH BOARD
Scotland's largest NHS board, contributing clinical sites and patient cohorts to European research in inflammatory diseases, autism, and precision medicine.
“Core contributor across PIBD-SETQuality (inflammatory bowel disease), 3TR (autoimmunity/inflammation), IDEA-FAST (immune-mediated inflammatory disorders), and ENSAT-HT (endocrine hypertension).”
PrimaryUK8 projects